Library / Repair / PNC-27
p53-MDM2 research peptide
PNC-27
Preclinical High caution
ClassAnticancer research peptide
Typical routes in papersExperimental only
Half-life contextResearch-only
EvidencePreclinical / controversial translational claims
What it is
PNC-27 is a p53-derived peptide studied to punch holes in membranes of cells that display certain cancer-associated proteins.
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- The intended research benefit is selective tumor-cell killing in models.
- This is not an immune “boost” or a gym peptide. Off-label underground oncology use is a red flag, not a protocol.
- Included because the name circulates; inclusion is not an endorsement.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
HDM-2 targeting peptide designed to disrupt cancer-cell membranes via membrane-pore formation in HDM-2-expressing cells.
Possible side effects / caveats
Unknown human tox, tumor-lysis theory, contamination risk, and false hope. Oncology belongs in trials and clinics.
Protocol ranges
| Source tier | Amount | Frequency / duration | Notes |
|---|---|---|---|
| Literature | Model-specific | Not a community dose table | No responsible “cited daily mcg” |
Numbers below and above are literature or community pointers, not a treatment plan. Approved products, when they exist, follow the official label — not a research vial.